Drug giant Novo Nordisk just reported some clinical trial data. Despite the seemingly good news, the stock crashed right afterward. There's a difference between a clinical success and a ...

The US Food and Drug Administration on Monday approved Hikma Pharmaceuticals’ generic version of Novo Nordisk’s diabetes drug, Victoza, clearing the way for the launch of another copy of the ...

The upcoming, all-new Chevy Spark EUV will join the brand’s lineup in Brazil this year as its most affordable fully electric ...

General Motors has a new model that’s sparking a lot of interest around the world. The automaker’s China joint venture […] ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

Sloan, offering “a car for every purse and purpose.” The 2025 Chevrolet Equinox EV changes that. Chevy launched this electric counterpart to its gasoline Equinox compact SUV for the 2024 model ...

Novo Nordisk (NVO) reported its newest GLP-1 product, CagriSema, provides an average of 22.7% weight loss, but that wasn't enough to convince investors, sparking a sell-off of the stock. "We are ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Elon Musk Admits To Using Weight Loss Medication Criticized By RFK Jr, Says He Prefers Mounjaro Over Miracle Drug Ozempic The world's richest man Elon Musk earlier this week admitted to using the ...

Novo Nordisk A/S’s failure to meet its own bar for success on a next-generation obesity shot shows the danger of promising too much in the cut-throat market for weight-loss drugs. The Danish ...

Novo Nordisk, for its part, has been working hard to enrich its cardiometabolic pipeline in areas beyond diabetes and obesity, where the company currently dominates the commercial market with its ...